Medicare Enrolled
Dr. Daniel Watrous, M.D.
Rheumatology · Visalia, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Watrous from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Watrous?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Watrous
Dr. Daniel Watrous is a rheumatology specialist in Visalia, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Watrous performed 229,629 Medicare services across 3,346 unique beneficiaries.
Between the years covered by Open Payments, Dr. Watrous received a total of $14,370 from 37 pharmaceutical and/or device companies across 669 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Watrous is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 2% volume in CA
$14,370 industry payments
Medicare Practice Summary
Medicare Utilization ↗229,629
Medicare services
Top 2% in CA for rheumatology
3,346
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~12,086 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
73,900 | $10 | $30 |
| Tocilizumab injection (Actemra) | 60,640 | $5 | $13 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
24,350 | $34 | $88 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
22,970 | $26 | $160 |
| Romosozumab injection (Evenity) for osteoporosis | 15,540 | $8 | $28 |
| Denosumab injection (Prolia/Xgeva) | 13,320 | $18 | $43 |
| Rituximab injection, 10 mg Administration of a 10 mg dose of rituximab medication via injection. |
9,160 | $64 | $155 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
4,014 | $87 | $270 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
978 | $50 | $270 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
956 | $11 | $67 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
925 | $0 | $5 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
651 | $23 | $110 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
550 | $105 | $345 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
382 | $112 | $415 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
310 | $13 | $85 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
192 | $8 | $40 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
183 | $1 | $7 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
160 | $42 | $175 |
| Orthovisc intra-articular injection An injection of hyaluronan or its derivative into a joint space to provide lubrication and cushioning. |
142 | $100 | $1,165 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
125 | $4 | $13 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
120 | $7 | $19 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
61 | $66 | $184 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
53.5% high complexity
44.6% medium
1.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,370
Total received (2018-2024)
Avg $2,053/year across 7 years
Top 22% in CA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
37
Companies
669
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,336 (85.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,897 (13.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$137 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,971
2023
$2,651
2022
$2,259
2021
$1,227
2020
$270
2019
$3,496
2018
$1,496
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$519
Janssen Biotech, Inc.
$427
ABBVIE INC.
$322
Boehringer Ingelheim Pharmaceuticals, Inc.
$231
ANI Pharmaceuticals, Inc.
$184
AstraZeneca Pharmaceuticals LP
$170
GlaxoSmithKline, LLC.
$167
Aurinia Pharma U.S., Inc.
$156
UCB, Inc.
$152
GENZYME CORPORATION
$130
Novartis Pharmaceuticals Corporation
$102
Genentech USA, Inc.
$83
E.R. Squibb & Sons, L.L.C.
$78
Alexion Pharmaceuticals, Inc.
$76
Organon Llc
$58
Octapharma USA, Inc.
$28
Lilly USA, LLC
$26
Radius Health, Inc.
$26
PFIZER INC.
$21
SCILEX PHARMACEUTICALS INC.
$17
Top 3 companies account for 42.7% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$3,516
Amgen Inc.
$1,510
ABBVIE INC.
$1,254
GlaxoSmithKline, LLC.
$868
AbbVie Inc.
$856
Novartis Pharmaceuticals Corporation
$732
UCB, Inc.
$698
E.R. Squibb & Sons, L.L.C.
$525
PFIZER INC.
$440
Celgene Corporation
$397
Genentech USA, Inc.
$397
AstraZeneca Pharmaceuticals LP
$379
Horizon Therapeutics plc
$349
AbbVie, Inc.
$334
ANI Pharmaceuticals, Inc.
$313
GENZYME CORPORATION
$284
Aurinia Pharma U.S., Inc.
$268
Boehringer Ingelheim Pharmaceuticals, Inc.
$256
Janssen Scientific Affairs, LLC
$217
Lilly USA, LLC
$187
Alexion Pharmaceuticals, Inc.
$96
Medtronic Vascular, Inc.
$79
Organon Llc
$58
Fresenius Kabi USA, LLC
$52
Kiniksa Pharmaceuticals, Ltd.
$45
MEDEXUS PHARMA, INC.
$35
Octapharma USA, Inc.
$28
Mallinckrodt Hospital Products Inc.
$26
Radius Health, Inc.
$26
Organon LLC
$25
Celltrion USA Inc.
$23
Horizon Pharma plc
$21
Ipsen Biopharmaceuticals, Inc
$18
NOVARTIS PHARMACEUTICALS CORPORATION
$18
SCILEX PHARMACEUTICALS INC.
$17
SANOFI-AVENTIS U.S. LLC
$12
MEDAC PHARMA, INC.
$11
Top 3 companies account for 43.7% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · EVENITY · Enbrel · HADLIMA · HUMIRA · Humira · IDACIO · ILARIS · INFLECTRA · KEVZARA · KRYSTEXXA · LUPKYNIS · LYRICA · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · Otezla · PENNSAID · PURIFIED CORTROPHIN GEL · Perjeta · REMICADE · RENFLEXIS · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · TALTZ · TAVNEOS · TEZSPIRE · TREMFYA · VenaSeal · XELJANZ · YUFLYMA · ZTLido
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Rheumatologists within 10 mi
4
Per 100K population
0.8
County median income
$69,489
Nearest hospital
KAWEAH HEALTH MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Watrous is a mixed practice specialist, with above-average Medicare volume (top 2% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Watrous experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Watrous performed 73,900 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Watrous receive payments from pharmaceutical companies?
Yes. Dr. Watrous received a total of $14,370 from 37 companies across 669 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Watrous's costs compare to other rheumatologists in Visalia?
Dr. Watrous's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Watrous) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Visalia
Browse rheumatologists in Visalia ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in CA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in CA
Which CA rheumatologists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology